A new study published online in the Journal of Intensive Medicine on June 17, 2025, highlights early and dynamic alterations in lymphocyte subsets following sepsis in elderly patients and their ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317’s ability to activate CD40 in a ...
CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding tumor targets and the CD3 protein on ...
AbCellera today announced new data on its PSMA x CD3 T-cell engagers, presented as a poster at the American Association for Cancer ResearchⓇ 116th Annual Meeting at the McCormick Place Convention ...
Growing cancer-targeting T-cells in a lab is only half the battle. They must be collected intact. A new IIT Bombay study has ...
The FDA has granted fast track designation (FTD) to LBL-034, an investigational GPRC5D/CD3 bispecific T-cell engager (BiTE), for patients with relapsed/refractory multiple myeloma (R/R MM).
South Korean pharmaceuticals Celltrion Inc. and Cyron Therapeutics Co. Ltd. are teaming up to discover and develop bispecific and trispecific antibodies, collectively called polyspecific antibodies, ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results